metformin has been researched along with Endometrial Hyperplasia in 42 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Endometrial Hyperplasia: Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART)." | 9.51 | A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. ( Kong, WY; Liu, ZA; Wu, X; Yan, L; Zhang, N; Zhao, XB, 2022) |
| " The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate." | 9.51 | Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022) |
| " The results of enrolled studies were pooled using meta-analysis to estimate the effect of progestin plus metformin on remission, recurrence, pregnancy rate and live birth rate." | 9.41 | Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023) |
| "This study showed that megestrol plus metformin was significantly better than megestrol alone for the treatment of endometrial hyperplasia without atypia." | 9.41 | The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. ( Aghajani, R; Arab, M; Ghahghaei-Nezamabadi, A; Khalagi, K; Sadeghi, S; Tehranian, A, 2021) |
| "To compare the efficacy in terms of histopathological response, clinical response and safety at the end of 6 months in patients with endometrial hyperplasia without atypia managed with Levonorgestrel intrauterine system alone versus patients managed with Levonorgestrel intrauterine system plus metformin." | 9.41 | A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women. ( Bagga, R; Jain, V; Kalra, J; Ravi, RD; Sachdeva, N; Srinivasan, R; Suri, V, 2021) |
| "To assess the efficacy of metformin in megestrol acetate (MA)-based fertility-sparing treatment for patients with atypical endometrial hyperplasia (AEH) and endometrioid endometrial cancer (EEC)." | 9.34 | Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. ( Chen, XJ; Cheng, YL; Du, Y; Guan, J; Gulinazi, Y; Liu, J; Luo, XZ; Ma, FH; Ning, CC; Shan, WW; Sun, L; Yang, BY; Yu, M; Zhang, HW; Zhu, Q, 2020) |
| "Metformin is comparable with megestrol for the treatment of simple endometrial hyperplasia." | 9.24 | A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia. ( Aminimoghaddam, S; Fazaeli, M; Kashanian, M; Sharifzadeh, F; Sheikhansari, N, 2017) |
| " We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC." | 9.22 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| " Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review." | 9.12 | Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021) |
| "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia." | 8.95 | Metformin for endometrial hyperplasia. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH." | 8.12 | Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. ( Chen, L; Li, R; Liu, J; Ning, Y; Zhao, Y; Zhu, X, 2022) |
| "The objective of the present study was to investigate the molecular mechanism underlying the role of metformin (Met) in reducing the risk of endometrial hyperplasia (EH)." | 7.96 | Metformin alleviates endometrial hyperplasia through the UCA1/miR‑144/TGF‑β1/AKT signaling pathway. ( Guo, M; Huang, W; Zhou, JJ, 2020) |
| "This study aimed to investigate the molecular mechanisms underlying the roles of metformin (MET) and Sorafenib (SOR) in the treatment of endometrial hyperplasia (EH) in polycystic ovary syndrome (PCOS)." | 7.96 | Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. ( Gao, ZH; Guo, XC; Ji, M; Li, L; Wang, QQ, 2020) |
| "The present study investigated long-term outcomes of medroxyprogesterone acetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia (AEH) and endometrial cancer (EC), and post-treatment conception." | 7.91 | Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. ( Habu, Y; Ishikawa, H; Kawarai, Y; Kobayashi, T; Mitsuhashi, A; Shozu, M; Usui, H, 2019) |
| "This study compared the antiproliferative effects of metformin and progesterone, via examination of the Bcl-2/Bax-caspase apoptotic pathway in estrogen-induced endometrial hyperplasia (EH) in 40 rats." | 7.88 | Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins. ( Akgun, H; Dolanbay, M; Eraslan Sahin, M; Ozcelik, B; Saatci, C; Sahin, E, 2018) |
| " We evaluated whether obesity exacerbates progression of endometrial hyperplasia (EH) using the PRCre/+ PTENflox/+ mouse model and examined if the type 2 diabetes drug, metformin, could prevent EH." | 7.85 | Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. ( Celestino, J; Iglesias, DA; Lu, KH; Schmandt, RE; Sun, CC; Yates, MS; Zhang, Q, 2017) |
| "Metformin has been shown to inhibit the growth of endometriotic implants, and reverse endometrial hyperplasia when combined with oral contraceptive in a case report." | 7.79 | Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. ( Kutuk, MS; Oner, G; Ozgun, MT; Ozturk, F; Serin, IS; Tas, M, 2013) |
| "To describe a case where pharmacist prescribing of metformin therapy resulted in unexplained vaginal bleeding in a patient later diagnosed with complex endometrial hyperplasia." | 7.79 | Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia. ( Houle, SK; Lyster, RL, 2013) |
| "The effects of metformin on S6K1, which is a crucial effector of mTOR signaling, and on endometrium were studied in a mouse model of endometrial hyperplasia induced by unopposed estradiol or tamoxifen." | 7.75 | Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. ( Erdemoglu, E; Giray, SG; Güney, M; Mungan, T; Take, G, 2009) |
| "Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC." | 6.82 | The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. ( Chen, XJ; Guan, J, 2022) |
| "Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes." | 6.50 | Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? ( Abu, J; Ariffin, R; Atiomo, W; Barrett, DA; Chapman, C; Deen, S; Khan, G; Nunns, D; Seedhouse, C; Shafiee, MN, 2014) |
| "To investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART)." | 5.51 | A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. ( Kong, WY; Liu, ZA; Wu, X; Yan, L; Zhang, N; Zhao, XB, 2022) |
| " The primary aim is to determine the efficacy of a levonorgestrel-releasing intrauterine device (LNG-IUD) plus metformin, or megestrol acetate (MA) plus metformin in achieving pathological complete response (pCR) at 12 months, as well as post-treatment pregnancy outcomes and recurrence rate." | 5.51 | Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr ( Liu, Z; Niu, J; Shi, C; Zhao, X, 2022) |
| "However, the established treatment for endometrial hyperplasia (progestogens) involves multiple side effects and leaves the risk of recurrence." | 5.43 | Metformin for endometrial hyperplasia: a Cochrane protocol. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Saner, JR; Shiwani, H, 2016) |
| " The results of enrolled studies were pooled using meta-analysis to estimate the effect of progestin plus metformin on remission, recurrence, pregnancy rate and live birth rate." | 5.41 | Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. ( Li, Y; Shao, F; Zhao, Y, 2023) |
| "To compare the efficacy in terms of histopathological response, clinical response and safety at the end of 6 months in patients with endometrial hyperplasia without atypia managed with Levonorgestrel intrauterine system alone versus patients managed with Levonorgestrel intrauterine system plus metformin." | 5.41 | A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women. ( Bagga, R; Jain, V; Kalra, J; Ravi, RD; Sachdeva, N; Srinivasan, R; Suri, V, 2021) |
| "This study showed that megestrol plus metformin was significantly better than megestrol alone for the treatment of endometrial hyperplasia without atypia." | 5.41 | The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial. ( Aghajani, R; Arab, M; Ghahghaei-Nezamabadi, A; Khalagi, K; Sadeghi, S; Tehranian, A, 2021) |
| "Two women with atypical endometrial hyperplasia complicating polycystic ovary syndrome (PCOS) had failed to respond to high-dose progestin therapy." | 5.35 | Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. ( Lin, JF; Shen, ZQ; Zhu, HT, 2008) |
| "To assess the efficacy of metformin in megestrol acetate (MA)-based fertility-sparing treatment for patients with atypical endometrial hyperplasia (AEH) and endometrioid endometrial cancer (EEC)." | 5.34 | Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. ( Chen, XJ; Cheng, YL; Du, Y; Guan, J; Gulinazi, Y; Liu, J; Luo, XZ; Ma, FH; Ning, CC; Shan, WW; Sun, L; Yang, BY; Yu, M; Zhang, HW; Zhu, Q, 2020) |
| "Metformin is comparable with megestrol for the treatment of simple endometrial hyperplasia." | 5.24 | A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia. ( Aminimoghaddam, S; Fazaeli, M; Kashanian, M; Sharifzadeh, F; Sheikhansari, N, 2017) |
| " We assessed the efficacy of metformin in preventing recurrence after medroxyprogesterone acetate (MPA) as fertility-sparing treatment for atypical endometrial hyperplasia (AEH) and EC." | 5.22 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. ( Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M, 2016) |
| "A total of 43 patients who were referred to our center for abnormal uterine bleeding and had a histologic diagnosis were disordered proliferative endometrium or simple endometrial hyperplasia were included and randomly distributed in two groups treated with metformin (500mg Bid) or megestrol (40mg daily), respectively, for three months." | 5.19 | Antiproliferative effect of metformin on the endometrium--a clinical trial. ( Bidadi, S; Foroughi, M; Ghojazadeh, M; Melli, MS; Tabrizi, AD, 2014) |
| "This pilot study included 16 EAH patients who met at least one metabolic syndrome (MS) criterion and received either adjunctive metformin plus MA (MET group) or MA monotherapy (MA group)." | 5.19 | Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. ( Chen, X; Gu, C; Luo, X; Ning, C; Shan, W; Wang, C; Zhang, Z; Zhou, Q, 2014) |
| " Studies of reproductive-aged women with atypical endometrial hyperplasia or early endometrial cancer who received progestin and metformin or progestin alone for fertility-sparing management, were included in the review." | 5.12 | Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. ( Blake, LE; Chae-Kim, J; Garg, G; Gavrilova-Jordan, L; Hayslip, CC; Kim, TT; Wu, Q, 2021) |
| "To determine the effectiveness and safety of metformin in treating women with endometrial hyperplasia." | 4.95 | Metformin for endometrial hyperplasia. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Sanner, JR; Shiwani, H, 2017) |
| "Regardless the high heterogeneity of the analyzed studies, the present review suggests that adjunct metformin treatment may assist in the reversal of atypical endometrial hyperplasia to normal endometrial histology, in the reduction of cell proliferation biomarkers implicated in tumor progression, and in the improvement of overall survival in endometrial cancer." | 4.95 | Effects of metformin on endometrial cancer: Systematic review and meta-analysis. ( Guerra, ENS; Lofrano-Porto, A; Meireles, CG; Pereira, SA; Rêgo, DF; Simeoni, LA; Valadares, LP, 2017) |
| "Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH." | 4.12 | Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. ( Chen, L; Li, R; Liu, J; Ning, Y; Zhao, Y; Zhu, X, 2022) |
| "This study aimed to investigate the molecular mechanisms underlying the roles of metformin (MET) and Sorafenib (SOR) in the treatment of endometrial hyperplasia (EH) in polycystic ovary syndrome (PCOS)." | 3.96 | Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. ( Gao, ZH; Guo, XC; Ji, M; Li, L; Wang, QQ, 2020) |
| "The objective of the present study was to investigate the molecular mechanism underlying the role of metformin (Met) in reducing the risk of endometrial hyperplasia (EH)." | 3.96 | Metformin alleviates endometrial hyperplasia through the UCA1/miR‑144/TGF‑β1/AKT signaling pathway. ( Guo, M; Huang, W; Zhou, JJ, 2020) |
| "The underlying mechanisms of polycystic ovarian syndrome (PCOS)-induced endometrial dysfunction are not fully understood, and although accumulating evidence shows that the use of metformin has beneficial effects in PCOS patients, the precise regulatory mechanisms of metformin on endometrial function under PCOS conditions have only been partially explored." | 3.91 | Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, ( Billig, H; Brännström, M; Cui, P; Hu, M; Li, J; Li, X; Shao, LR; Vestin, E; Wang, T; Zhang, J; Zhang, Y, 2019) |
| "The present study investigated long-term outcomes of medroxyprogesterone acetate (MPA) plus metformin therapy in terms of control of atypical endometrial hyperplasia (AEH) and endometrial cancer (EC), and post-treatment conception." | 3.91 | Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. ( Habu, Y; Ishikawa, H; Kawarai, Y; Kobayashi, T; Mitsuhashi, A; Shozu, M; Usui, H, 2019) |
| "This study compared the antiproliferative effects of metformin and progesterone, via examination of the Bcl-2/Bax-caspase apoptotic pathway in estrogen-induced endometrial hyperplasia (EH) in 40 rats." | 3.88 | Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins. ( Akgun, H; Dolanbay, M; Eraslan Sahin, M; Ozcelik, B; Saatci, C; Sahin, E, 2018) |
| " We evaluated whether obesity exacerbates progression of endometrial hyperplasia (EH) using the PRCre/+ PTENflox/+ mouse model and examined if the type 2 diabetes drug, metformin, could prevent EH." | 3.85 | Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. ( Celestino, J; Iglesias, DA; Lu, KH; Schmandt, RE; Sun, CC; Yates, MS; Zhang, Q, 2017) |
| "Metformin has been shown to inhibit the growth of endometriotic implants, and reverse endometrial hyperplasia when combined with oral contraceptive in a case report." | 3.79 | Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. ( Kutuk, MS; Oner, G; Ozgun, MT; Ozturk, F; Serin, IS; Tas, M, 2013) |
| "To describe a case where pharmacist prescribing of metformin therapy resulted in unexplained vaginal bleeding in a patient later diagnosed with complex endometrial hyperplasia." | 3.79 | Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia. ( Houle, SK; Lyster, RL, 2013) |
| "The effects of metformin on S6K1, which is a crucial effector of mTOR signaling, and on endometrium were studied in a mouse model of endometrial hyperplasia induced by unopposed estradiol or tamoxifen." | 3.75 | Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. ( Erdemoglu, E; Giray, SG; Güney, M; Mungan, T; Take, G, 2009) |
| "Preclinical studies in endometrial cancer (EC) show that metformin reduces cellular proliferation by PI3K-AKT-mTOR inhibition." | 2.82 | Measuring the biological effect of presurgical metformin treatment in endometrial cancer. ( Ali, S; Crosbie, EJ; Gilmour, K; Kitchener, HC; Kitson, S; McVey, R; Pemberton, P; Renehan, AG; Roberts, C; Sivalingam, VN, 2016) |
| "The conservative management of atypical endometrial hyperplasia and early-stage endometrial cancer is feasible, provided a strong desire for childbearing and permitting clinical-pathological conditions." | 2.82 | Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women. ( Bosco, M; Braga, A; Cianci, S; Dababou, S; Franchi, MP; Frigerio, M; Gardella, B; Garzon, S; Laganà, AS; Torella, M; Uccella, S; Zorzato, PC, 2022) |
| "Metformin has been demonstrated to play an anti-cancer role in multiple cancers including EC." | 2.82 | The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer. ( Chen, XJ; Guan, J, 2022) |
| "Endometrial hyperplasia was associated with better outcomes." | 2.72 | Fertility-sparing management for endometrial cancer: review of the literature. ( Bosco, M; Franchi, MP; Garzon, S; Mariani, A; Student, V; Uccella, S; Zorzato, PC, 2021) |
| "Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes." | 2.50 | Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? ( Abu, J; Ariffin, R; Atiomo, W; Barrett, DA; Chapman, C; Deen, S; Khan, G; Nunns, D; Seedhouse, C; Shafiee, MN, 2014) |
| "This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility." | 1.51 | Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. ( Chen, X; Luo, X; Ning, C; Shan, W; Shi, Y; Xie, B; Xie, L; Xu, Y; Yang, B; Zhang, H; Zhu, Q, 2019) |
| "However, the established treatment for endometrial hyperplasia (progestogens) involves multiple side effects and leaves the risk of recurrence." | 1.43 | Metformin for endometrial hyperplasia: a Cochrane protocol. ( Atiomo, W; Clement, NS; Mulvaney, CA; Oliver, TR; Saner, JR; Shiwani, H, 2016) |
| "Two women with atypical endometrial hyperplasia complicating polycystic ovary syndrome (PCOS) had failed to respond to high-dose progestin therapy." | 1.35 | Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. ( Lin, JF; Shen, ZQ; Zhu, HT, 2008) |
| "This patient's atypical endometrial hyperplasia regressed after the initiation of treatment with an insulin-sensitizing agent." | 1.32 | Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. ( Damario, MA; Dumesic, DA; Kalli, KR; Session, DR; Tummon, IS, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (7.14) | 29.6817 |
| 2010's | 20 (47.62) | 24.3611 |
| 2020's | 19 (45.24) | 2.80 |
| Authors | Studies |
|---|---|
| Chae-Kim, J | 1 |
| Garg, G | 1 |
| Gavrilova-Jordan, L | 1 |
| Blake, LE | 1 |
| Kim, TT | 1 |
| Wu, Q | 1 |
| Hayslip, CC | 1 |
| Liu, J | 2 |
| Zhao, Y | 2 |
| Chen, L | 1 |
| Li, R | 1 |
| Ning, Y | 1 |
| Zhu, X | 1 |
| Kong, WY | 1 |
| Liu, ZA | 1 |
| Zhang, N | 1 |
| Wu, X | 1 |
| Zhao, XB | 1 |
| Yan, L | 1 |
| Uccella, S | 2 |
| Zorzato, PC | 2 |
| Dababou, S | 1 |
| Bosco, M | 2 |
| Torella, M | 1 |
| Braga, A | 1 |
| Frigerio, M | 1 |
| Gardella, B | 1 |
| Cianci, S | 1 |
| Laganà, AS | 1 |
| Franchi, MP | 2 |
| Garzon, S | 2 |
| Zhao, X | 1 |
| Niu, J | 1 |
| Shi, C | 1 |
| Liu, Z | 1 |
| Guan, J | 4 |
| Chen, XJ | 4 |
| Ushijima, K | 2 |
| Tsuda, N | 1 |
| Yamagami, W | 1 |
| Mitsuhashi, A | 5 |
| Mikami, M | 1 |
| Yaegashi, N | 1 |
| Enomoto, T | 1 |
| Shao, F | 1 |
| Li, Y | 1 |
| Habu, Y | 1 |
| Kobayashi, T | 1 |
| Kawarai, Y | 1 |
| Ishikawa, H | 1 |
| Usui, H | 1 |
| Shozu, M | 4 |
| Guo, M | 1 |
| Zhou, JJ | 1 |
| Huang, W | 1 |
| Yang, BY | 1 |
| Gulinazi, Y | 1 |
| Du, Y | 1 |
| Ning, CC | 1 |
| Cheng, YL | 1 |
| Shan, WW | 1 |
| Luo, XZ | 1 |
| Zhang, HW | 1 |
| Zhu, Q | 2 |
| Ma, FH | 1 |
| Sun, L | 1 |
| Yu, M | 1 |
| Acosta-Torres, S | 1 |
| Murdock, T | 1 |
| Matsuno, R | 1 |
| Beavis, AL | 1 |
| Stone, RL | 1 |
| Wethington, SL | 1 |
| Levinson, K | 1 |
| Grumbine, F | 1 |
| Ferriss, JS | 1 |
| Tanner, EJ | 1 |
| Fader, AN | 1 |
| Atiomo, W | 4 |
| Kawasaki, Y | 1 |
| Hori, M | 1 |
| Fujiwara, T | 1 |
| Hanaoka, H | 2 |
| Tehranian, A | 1 |
| Ghahghaei-Nezamabadi, A | 1 |
| Arab, M | 1 |
| Khalagi, K | 1 |
| Aghajani, R | 1 |
| Sadeghi, S | 1 |
| Student, V | 1 |
| Mariani, A | 1 |
| Hu, M | 2 |
| Zhang, Y | 2 |
| Li, X | 2 |
| Cui, P | 2 |
| Sferruzzi-Perri, AN | 1 |
| Brännström, M | 2 |
| Shao, LR | 2 |
| Billig, H | 2 |
| Ravi, RD | 1 |
| Kalra, J | 1 |
| Srinivasan, R | 1 |
| Bagga, R | 1 |
| Jain, V | 1 |
| Suri, V | 1 |
| Sachdeva, N | 1 |
| Meireles, CG | 1 |
| Pereira, SA | 1 |
| Valadares, LP | 1 |
| Rêgo, DF | 1 |
| Simeoni, LA | 1 |
| Guerra, ENS | 1 |
| Lofrano-Porto, A | 1 |
| Clement, NS | 2 |
| Oliver, TR | 2 |
| Shiwani, H | 2 |
| Sanner, JR | 1 |
| Mulvaney, CA | 2 |
| Sahin, E | 1 |
| Eraslan Sahin, M | 1 |
| Dolanbay, M | 1 |
| Ozcelik, B | 1 |
| Akgun, H | 1 |
| Saatci, C | 1 |
| Yang, B | 1 |
| Xu, Y | 1 |
| Xie, L | 1 |
| Shan, W | 2 |
| Ning, C | 2 |
| Xie, B | 1 |
| Shi, Y | 1 |
| Luo, X | 2 |
| Zhang, H | 1 |
| Chen, X | 2 |
| Wang, T | 1 |
| Zhang, J | 1 |
| Li, J | 1 |
| Vestin, E | 1 |
| Wang, QQ | 1 |
| Guo, XC | 1 |
| Li, L | 1 |
| Gao, ZH | 1 |
| Ji, M | 1 |
| Shafiee, MN | 1 |
| Khan, G | 1 |
| Ariffin, R | 1 |
| Abu, J | 1 |
| Chapman, C | 1 |
| Deen, S | 1 |
| Nunns, D | 1 |
| Barrett, DA | 1 |
| Seedhouse, C | 1 |
| Lyster, RL | 1 |
| Houle, SK | 1 |
| Zhang, Q | 2 |
| Schmandt, R | 1 |
| Celestino, J | 2 |
| McCampbell, A | 1 |
| Yates, MS | 2 |
| Urbauer, DL | 1 |
| Broaddus, RR | 1 |
| Loose, DS | 1 |
| Shipley, GL | 1 |
| Lu, KH | 2 |
| Kim, MK | 1 |
| Seong, SJ | 1 |
| Wang, C | 1 |
| Zhang, Z | 1 |
| Gu, C | 1 |
| Zhou, Q | 1 |
| Tabrizi, AD | 1 |
| Melli, MS | 1 |
| Foroughi, M | 1 |
| Ghojazadeh, M | 1 |
| Bidadi, S | 1 |
| Zhou, R | 1 |
| Yang, Y | 1 |
| Lu, Q | 1 |
| Wang, J | 1 |
| Miao, Y | 1 |
| Wang, S | 1 |
| Wang, Z | 1 |
| Zhao, C | 1 |
| Wei, L | 1 |
| Sato, Y | 1 |
| Kiyokawa, T | 1 |
| Koshizaka, M | 1 |
| Sivalingam, VN | 1 |
| Kitson, S | 1 |
| McVey, R | 1 |
| Roberts, C | 1 |
| Pemberton, P | 1 |
| Gilmour, K | 1 |
| Ali, S | 1 |
| Renehan, AG | 1 |
| Kitchener, HC | 1 |
| Crosbie, EJ | 1 |
| Saner, JR | 1 |
| Sharifzadeh, F | 1 |
| Aminimoghaddam, S | 1 |
| Kashanian, M | 1 |
| Fazaeli, M | 1 |
| Sheikhansari, N | 1 |
| Iglesias, DA | 1 |
| Sun, CC | 1 |
| Schmandt, RE | 1 |
| Shen, ZQ | 1 |
| Zhu, HT | 1 |
| Lin, JF | 1 |
| Erdemoglu, E | 1 |
| Güney, M | 1 |
| Giray, SG | 1 |
| Take, G | 1 |
| Mungan, T | 1 |
| Tas, M | 1 |
| Kutuk, MS | 1 |
| Serin, IS | 1 |
| Ozgun, MT | 1 |
| Oner, G | 1 |
| Ozturk, F | 1 |
| Session, DR | 1 |
| Kalli, KR | 1 |
| Tummon, IS | 1 |
| Damario, MA | 1 |
| Dumesic, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| Endometrial Cancer Recurrence in Patients Taking Metformin[NCT05192850] | 100 participants (Anticipated) | Observational | 2021-12-27 | Active, not recruiting | |||
| The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.[NCT04385667] | Phase 2/Phase 3 | 143 participants (Actual) | Interventional | 2020-05-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for metformin and Endometrial Hyperplasia
| Article | Year |
|---|---|
Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasm | 2021 |
Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.
Topics: Conservative Treatment; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservati | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2022 |
Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Metformin; N | 2023 |
New therapeutic approaches for the fertility-sparing treatment of endometrial cancer.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Orga | 2020 |
Fertility-sparing management for endometrial cancer: review of the literature.
Topics: Administration, Oral; Drug Carriers; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertili | 2021 |
Effects of metformin on endometrial cancer: Systematic review and meta-analysis.
Topics: Biomarkers, Tumor; Chemotherapy, Adjuvant; Endometrial Hyperplasia; Endometrial Neoplasms; Endometri | 2017 |
Metformin for endometrial hyperplasia.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Disease Progression; Endometrial Hyperplasia; Female; | 2017 |
Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Metformin; Polycystic Ovary Syndrome | 2014 |
11 trials available for metformin and Endometrial Hyperplasia
| Article | Year |
|---|---|
A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes.
Topics: Endometrial Hyperplasia; Female; Humans; Hyperplasia; Infertility, Female; Metformin; Polycystic Ova | 2022 |
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial pr
Topics: Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Fema | 2022 |
Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; China; Drug Therapy, Combination; Endometrial Hy | 2020 |
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Protocols; Disease-Free Survival; Dose-Response Rel | 2020 |
The impact of adjunctive metformin to progesterone for the treatment of non-atypical endometrial hyperplasia in a randomized fashion, a placebo-controlled, double blind clinical trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Double-Blind Method; Drug Therapy, Combination; Endometrial | 2021 |
A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women.
Topics: Adult; Contraceptive Agents, Hormonal; Drug Therapy, Combination; Endometrial Hyperplasia; Female; H | 2021 |
Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.
Topics: Adult; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Endometrial Hyperplasia; Female; | 2014 |
Antiproliferative effect of metformin on the endometrium--a clinical trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Atrophy; Carcinoma, Endometrioid; Endometrial Hyperplasia; E | 2014 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial | 2016 |
Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carcinoma, Endometrioid; Endometrial Hyperplasia; | 2016 |
A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia.
Topics: Adult; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents | 2017 |
22 other studies available for metformin and Endometrial Hyperplasia
| Article | Year |
|---|---|
Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Endometrial Hyperplasia; Endometrium; Female; Glucose Transporte | 2022 |
Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Topics: Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservat | 2023 |
Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; F | 2019 |
Fertility sparing treatment for early stage endometrial cancer: current situation and new strategy.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Humans; Metformin; Progestins | 2019 |
Metformin alleviates endometrial hyperplasia through the UCA1/miR‑144/TGF‑β1/AKT signaling pathway.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell Line, Tumor; Endometrial Hyperplasia; Fema | 2020 |
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cohort Studies; Endometria | 2020 |
Is there any move to use metformin for endometrial hyperplasia in routine clinical practice?
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Hypoglycemic Agents; Me | 2020 |
TLR4-Associated IRF-7 and NFκB Signaling Act as a Molecular Link Between Androgen and Metformin Activities and Cytokine Synthesis in the PCOS Endometrium.
Topics: Adult; Androgens; Cytokines; Endometrial Hyperplasia; Endometrium; Female; Humans; Interferon Regula | 2021 |
Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins.
Topics: Animals; Apoptosis; Disease Models, Animal; Endometrial Hyperplasia; Estradiol; Female; Metformin; P | 2018 |
Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Topics: Administration, Oral; Adult; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Prese | 2019 |
Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer,
Topics: Adult; Apoptosis; Blotting, Western; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Fe | 2019 |
Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Drug Synergism; Endometrial Hyperplasi | 2020 |
Abnormal vaginal bleeding following pharmacist prescribing of metformin leads to the detection of complex endometrial hyperplasia.
Topics: Diabetes Mellitus; Drug Prescriptions; Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents; | 2013 |
CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity.
Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Endometrial Hyperplasia; Endom | 2014 |
Conservative treatment for atypical endometrial hyperplasia: what is the most effective therapeutic method?
Topics: Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents; Meges | 2014 |
Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; China; Endometrial Hyperplasia; Endome | 2015 |
Metformin for endometrial hyperplasia: a Cochrane protocol.
Topics: Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents; Hysterectomy; Metformin; Progestins; Q | 2016 |
Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.
Topics: Adiponectin; Animals; Body Weight; Endometrial Hyperplasia; Female; Hypoglycemic Agents; Metformin; | 2017 |
Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives.
Topics: Adult; Contraceptives, Oral, Hormonal; Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents; | 2008 |
Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia.
Topics: Animals; Carrier Proteins; Cell Proliferation; Disease Models, Animal; Endometrial Hyperplasia; Endo | 2009 |
Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats.
Topics: Animals; Cell Proliferation; Endometrial Hyperplasia; Endometrium; Estradiol; Female; Metformin; Pro | 2013 |
Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent.
Topics: Administration, Oral; Adult; Endometrial Hyperplasia; Female; Humans; Hypoglycemic Agents; Metformin | 2003 |